Paeds SAQs · adolescent-and-young-adult-medicine
Medication adherence and treatment fatigue — formative SAQs
Two formative short-answer questions on adolescent medication adherence assessment, treatment fatigue, multimodal measurement, and a tailored, non-judgemental adherence-promotion plan.
On this page & tools
Target exams
SAQ 1 — Assessment and measurement (10 marks)
A 15-year-old with epilepsy has been seizure-free for two years on a single antiseizure medicine. At review the level is subtherapeutic; the young person reports taking every dose and asks whether they can stop now that they feel well. [1] [4]
Questions
- Define medication adherence and distinguish its three phases. (3 marks) [3]
- Outline how you would assess adherence in this young person, naming the modalities and their limitations. (4 marks) [1] [4]
- Explain the principle behind the young person's request to stop, and your immediate non-pharmacological response. (3 marks) [1] [5]
Model answer
Definition and phases (3). Adherence is the extent to which a person's behaviour in taking medication corresponds to agreed recommendations. It has three phases: initiation (whether the medicine is ever started), implementation (whether it is taken as prescribed day to day), and persistence (whether it is continued over time). A subtherapeutic level with reported perfection is an implementation failure until shown otherwise, and the request to stop is a persistence question. [3] [1]
Assessment (4). Open with a non-judgemental, normalising frame and time alone. Take a structured, behavioural history (of the last seven days, how many had all doses). Measure multimodally: self-report opens the conversation; refill or pharmacy records estimate implementation over time; the drug level and any objective data triangulate it, while recognising white-coat adherence can raise a pre-visit level and mask chronic non-adherence. Screen for mood and the meaning of the medicine. No single measure captures the whole behaviour. [1] [4]
Request to stop (3). This is the asymptomatic-on-treatment trap: success of the medicine removes the symptoms that signalled its necessity, so the young person reasons it is no longer needed. Withdrawal risks seizure cluster and raises sudden unexpected death in epilepsy risk. Respond with curiosity rather than confrontation — explore what stopping would mean, share the rationale for continuation, and build a shared plan rather than issue an instruction. [1] [5]
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References6Show ledgerHide ledger
- [1]Hanghøj S, Boisen KA Self-reported barriers to medication adherence among chronically ill adolescents: a systematic review. Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2014.PMID 24182940
- [2]Kahana S, Drotar D, Frazier T Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. Journal of pediatric psychology, 2008.PMID 18192300
- [3]Pai AL, Drotar D Treatment adherence impact: the systematic assessment and quantification of the impact of treatment adherence on pediatric medical and psychological outcomes. Journal of pediatric psychology, 2010.PMID 19710252
- [4]Gutierrez-Colina AM, Smith AW, Mara CA, Modi AC Adherence barriers in pediatric epilepsy: From toddlers to young adults. Epilepsy & behavior : E&B, 2018.PMID 29433948
- [5]Drotar D Strategies of adherence promotion in the management of pediatric chronic conditions. Journal of developmental and behavioral pediatrics : JDBP, 2013.PMID 24247913
- [6]Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L Motivational Interviewing Improves Medication Adherence: a Systematic Review and Meta-analysis. Journal of general internal medicine, 2016.PMID 27160414